A highly sensitive ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method was developed for the quantification of vancomycin (VAN) in low volumes of rabbit serum. For each analysis,...A highly sensitive ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method was developed for the quantification of vancomycin (VAN) in low volumes of rabbit serum. For each analysis, 2 μL rabbit serum was precipitated with methanol that contained the internal standard teicoplanin (TEI). The supernatant was transferred into a 384 well-plate, diluted with water, covered with a pierceable silicone mat and 5 μL was analyzed in positive ionization mode. The UHPLC-MS/MS consisted of an Agilent 1290 Infinity UHPLC system connected to an AB Sciex QTrap®5500 hybrid linear ion-trap triple quadrupole mass spectrometer equipped with a Turbo Spray source. Chromatographic separation was achieved using a Waters Acquity UPLC BEH C18 (1.7 μm, 2.1 mm × 100 mm) column, a VanGuard (1.7 μm, 2.1 × 5 mm) guard column and a mobile phase of water and methanol both containing 5 mM ammonium acetate with 0.1% formic acid. VAN was quantified with multiple reaction monitoring using the transitions of m/z 725.5/144.2, and TEI was monitored at m/z 940.6/316.4. The accuracy, precision, linearity, range and lower limit of quantification (LLOQ) were determined. The accuracy was ≤9.93% and the precision was ≤10.6%. The range was established as 0.1 to 40 μg·mL-1. The LLOQ was 0.1 μg·mL-1 VAN requiring 2 μL of sample with an accuracy of -20.2% and precision of 8.39%. The method was applied successfully to determine the VAN concentrations in rabbit serum after the i.v. administration of VAN via implanted ear catheters.展开更多
目的利用同位素标记相对和绝对定量(isobaric tag for relative and absolute quantification,iTRAQ)蛋白质组学技术,分析糖尿病增殖期视网膜病变(proliferative diabetic retinopathy,PDR)患者与糖尿病无视网膜病变患者(diabetes patie...目的利用同位素标记相对和绝对定量(isobaric tag for relative and absolute quantification,iTRAQ)蛋白质组学技术,分析糖尿病增殖期视网膜病变(proliferative diabetic retinopathy,PDR)患者与糖尿病无视网膜病变患者(diabetes patients without retina diseases,NDR)之间蛋白表达的差异,寻找PDR的候选血清标志物。方法收集2016年至2017年首都医科大学附属北京同仁医院内分泌科住院的PDR患者21例,以及性别年龄匹配的NDR患者21例。患者血清样本混匀后提取蛋白,采用iTRAQ标记,并进行液相质谱-串联质谱检测(liquid chromatograph-mass spectrometer and mass spectrometer,LC-MS/MS)分析,筛选出差异蛋白行基因本体论(Gene Ontology,GO)数据库功能富集及京都基因与基因组百科全书(Kyoto Encyclopedia of Genes and Genome,KEGG)通路显著性富集分析。对相对定量结果进行独立样本t检验,通过差异倍数(fold change,FC)和P值判定蛋白表达量变化。结果以差异倍数>1.2倍(上/下调),P值≤0.05为标准,筛选出差异蛋白29个,其中PDR组上调蛋白8个,下调蛋白21个。通过对差异蛋白的GO功能显著性富集分析,结果显示,差异基因的功能可分为生物过程、细胞组分和分子功能三个板块。差异表达基因功能涉及生物调节、细胞组成、细胞代谢过程、细胞结合和催化活性等方面。KEGG通路显著性分析显示,上调最为明显的血管紧张素转换酶(angiotensin converting enzyme,ACE)参与肾素-血管紧张素系统(renin angiotensin system,RAS)、肾素分泌等通路,上调蛋白——胰岛素样生长因子I(insulin like growth factor I,IGF-1)参与HIF-1、FoxO、mTOR、PI3K-Akt和AMPK等多条与代谢相关的信号通路。下调显著的蛋白——肌球蛋白6(myosin-6)参与心肌细胞收缩和信号传导通路。结论采用iTRAQ蛋白质组学分析显示,PDR患者与NDR患者存在多种蛋白表达差异,ACE、IGF-1和Myosin-6有望作为糖尿病视网膜病变候选血清诊断标志物,未来可能为PDR的诊断和治疗提供新的靶点。展开更多
受体激动剂类药物在畜牧业中仍存在非法使用的风险,对消费者健康造成潜在威胁。本文采用液相色谱-质谱联用技术(Liquid Chromatography-Tandem Mass Spectrometry,LC-MS/MS)建立了一种检测猪肉中β-受体激动剂类药物残留的方法。样品经...受体激动剂类药物在畜牧业中仍存在非法使用的风险,对消费者健康造成潜在威胁。本文采用液相色谱-质谱联用技术(Liquid Chromatography-Tandem Mass Spectrometry,LC-MS/MS)建立了一种检测猪肉中β-受体激动剂类药物残留的方法。样品经酶解、净化、浓缩后,采用LC-MS/MS在多反应监测(Multiple Reaction Monitoring,MRM)模式下进行定性定量分析。优化后的前处理条件为甲醇-水(70∶30,v/v)作为提取溶剂,37℃β-葡萄糖醛酸苷酶水浴酶解12 h,固相萃取净化。优化后的仪器条件为采用C18色谱柱,0.1%甲酸水溶液和乙腈为流动相,梯度洗脱。4种β-受体激动剂在给定浓度范围内与响应值呈良好的线性关系,相关系数均大于0.99;日内和日间相对标准偏差均小于10%,回收率为87.9%~92.5%,基质效应值在90.4%~109.7%。该方法满足肉制品中β-受体激动剂类药物残留检测的要求。展开更多
To identify acute renal allograft rejection biomarkers in human serum, two-dimensional differential in-gel electrophoresis （2-D DIGE） and reversed phase high-performance liquid chromatography （RP-HPLC） followed by...To identify acute renal allograft rejection biomarkers in human serum, two-dimensional differential in-gel electrophoresis （2-D DIGE） and reversed phase high-performance liquid chromatography （RP-HPLC） followed by electrospray ionization mass spectrometry （ESI-MS） were used. Serum samples from renal allograft patients and normal volunteers were divided into three groups： acute rejec- tion （AR）, stable renal function （SRF） and normal volunteer （N）. Serum samples were firstly processed using Multiple Affinity Removal Column to selectively remove the highest abundance proteins. Differentially expressed proteins were analyzed using 2-D DIGE. These differential protein spots were excised, digested by trypsin, and identified by RP-HPLC-ESI/MS. Twenty-two differentially expressed proteins were identified in serum from AR group. These proteins included complement C9 precursor, apolipoprotein A-IV precursor, vitamin D-binding protein precursor, beta-2-glycoprotein 1 precursor, etc. Vitamin D-binding protein, one of these proteins, was confirmed by ELISA in the independent set of serum samples. In conclusion, the differentially expressed proteins as serum biomarker candidates may provide the basis of acute rejection noninvasive diagnosis. Confirmed vitamin D-binding protein may be one of serum biomarkers of acute rejection. Furthermore, it may provide great insights into understanding the mechanisms and potential treatment strategy of acute rejection.展开更多
BACKGROUND Primary biliary cholangitis(PBC)and autoimmune hepatitis(AIH)are two unexplained immune diseases.The golden standard for diagnosis of these diseases requires a liver biopsy.Liver biopsy is not widely accept...BACKGROUND Primary biliary cholangitis(PBC)and autoimmune hepatitis(AIH)are two unexplained immune diseases.The golden standard for diagnosis of these diseases requires a liver biopsy.Liver biopsy is not widely accepted by patients because of its invasive nature,and atypical liver histology can confuse diagnosis.In view of the lack of effective diagnostic markers for PBC and AIH,combined with the increasingly mature metabolomics technologies,including full-contour metabolomics and target.AIM To determine non-invasive,reliable,and sensitive biochemical markers for the differential diagnosis of PBC and AIH.METHODS Serum samples from 54 patients with PBC,26 patients with AIH and 30 healthy controls were analyzed by Ultra-high performance liquid chromatographytandem mass spectrometry serum metabolomics.The metabolites and metabolic pathways were identified,and the metabolic changes,metabolic pathways and inter-group differences between PBC and AIH were analyzed.Fifteen kinds of target metabolites of bile acids(BAs)were quantitatively analyzed by SRM,and the differential metabolites related to the diagnosis of PBC were screened by receiver operating characteristic curve analysis.RESULTS We found the changes in the levels of amino acids,BAs,organic acids,phospholipids,choline,sugar,and sugar alcohols in patients with PBC and AIH.Furthermore,the SRM assay of BAs revealed the increased levels of chenodeoxycholic acid,lithocholic acid(LCA),taurolithocholic acid(TLCA),and LCA+TLCA in the PBC group compared with those in the AIH group.The levels of BAs may be used as biomarkers to differentiate PBC from AIH diseases.The levels of glycochenodeoxycholic acid,glycochenodeoxycholic sulfate,and taurodeoxycholic acid were gradually elevated with the increase of Child-Pugh class,which was correlated with the severity of disease.CONCLUSION The results demonstrated that the levels of BAs could serve as potential biomarkers for the early diagnosis and assessment of the severity of PBC and AIH.展开更多
基金supported by the operating grant of the Collaborative Health Research Project,Natural Sciences and Engineering Research Council of Canada,and Canadian Institute of Health Research(CHRPJ 385967).
文摘A highly sensitive ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method was developed for the quantification of vancomycin (VAN) in low volumes of rabbit serum. For each analysis, 2 μL rabbit serum was precipitated with methanol that contained the internal standard teicoplanin (TEI). The supernatant was transferred into a 384 well-plate, diluted with water, covered with a pierceable silicone mat and 5 μL was analyzed in positive ionization mode. The UHPLC-MS/MS consisted of an Agilent 1290 Infinity UHPLC system connected to an AB Sciex QTrap®5500 hybrid linear ion-trap triple quadrupole mass spectrometer equipped with a Turbo Spray source. Chromatographic separation was achieved using a Waters Acquity UPLC BEH C18 (1.7 μm, 2.1 mm × 100 mm) column, a VanGuard (1.7 μm, 2.1 × 5 mm) guard column and a mobile phase of water and methanol both containing 5 mM ammonium acetate with 0.1% formic acid. VAN was quantified with multiple reaction monitoring using the transitions of m/z 725.5/144.2, and TEI was monitored at m/z 940.6/316.4. The accuracy, precision, linearity, range and lower limit of quantification (LLOQ) were determined. The accuracy was ≤9.93% and the precision was ≤10.6%. The range was established as 0.1 to 40 μg·mL-1. The LLOQ was 0.1 μg·mL-1 VAN requiring 2 μL of sample with an accuracy of -20.2% and precision of 8.39%. The method was applied successfully to determine the VAN concentrations in rabbit serum after the i.v. administration of VAN via implanted ear catheters.
文摘目的利用同位素标记相对和绝对定量(isobaric tag for relative and absolute quantification,iTRAQ)蛋白质组学技术,分析糖尿病增殖期视网膜病变(proliferative diabetic retinopathy,PDR)患者与糖尿病无视网膜病变患者(diabetes patients without retina diseases,NDR)之间蛋白表达的差异,寻找PDR的候选血清标志物。方法收集2016年至2017年首都医科大学附属北京同仁医院内分泌科住院的PDR患者21例,以及性别年龄匹配的NDR患者21例。患者血清样本混匀后提取蛋白,采用iTRAQ标记,并进行液相质谱-串联质谱检测(liquid chromatograph-mass spectrometer and mass spectrometer,LC-MS/MS)分析,筛选出差异蛋白行基因本体论(Gene Ontology,GO)数据库功能富集及京都基因与基因组百科全书(Kyoto Encyclopedia of Genes and Genome,KEGG)通路显著性富集分析。对相对定量结果进行独立样本t检验,通过差异倍数(fold change,FC)和P值判定蛋白表达量变化。结果以差异倍数>1.2倍(上/下调),P值≤0.05为标准,筛选出差异蛋白29个,其中PDR组上调蛋白8个,下调蛋白21个。通过对差异蛋白的GO功能显著性富集分析,结果显示,差异基因的功能可分为生物过程、细胞组分和分子功能三个板块。差异表达基因功能涉及生物调节、细胞组成、细胞代谢过程、细胞结合和催化活性等方面。KEGG通路显著性分析显示,上调最为明显的血管紧张素转换酶(angiotensin converting enzyme,ACE)参与肾素-血管紧张素系统(renin angiotensin system,RAS)、肾素分泌等通路,上调蛋白——胰岛素样生长因子I(insulin like growth factor I,IGF-1)参与HIF-1、FoxO、mTOR、PI3K-Akt和AMPK等多条与代谢相关的信号通路。下调显著的蛋白——肌球蛋白6(myosin-6)参与心肌细胞收缩和信号传导通路。结论采用iTRAQ蛋白质组学分析显示,PDR患者与NDR患者存在多种蛋白表达差异,ACE、IGF-1和Myosin-6有望作为糖尿病视网膜病变候选血清诊断标志物,未来可能为PDR的诊断和治疗提供新的靶点。
基金supported by a grant from National Basic Research 973 Program of China (No.2009CB522407)
文摘To identify acute renal allograft rejection biomarkers in human serum, two-dimensional differential in-gel electrophoresis （2-D DIGE） and reversed phase high-performance liquid chromatography （RP-HPLC） followed by electrospray ionization mass spectrometry （ESI-MS） were used. Serum samples from renal allograft patients and normal volunteers were divided into three groups： acute rejec- tion （AR）, stable renal function （SRF） and normal volunteer （N）. Serum samples were firstly processed using Multiple Affinity Removal Column to selectively remove the highest abundance proteins. Differentially expressed proteins were analyzed using 2-D DIGE. These differential protein spots were excised, digested by trypsin, and identified by RP-HPLC-ESI/MS. Twenty-two differentially expressed proteins were identified in serum from AR group. These proteins included complement C9 precursor, apolipoprotein A-IV precursor, vitamin D-binding protein precursor, beta-2-glycoprotein 1 precursor, etc. Vitamin D-binding protein, one of these proteins, was confirmed by ELISA in the independent set of serum samples. In conclusion, the differentially expressed proteins as serum biomarker candidates may provide the basis of acute rejection noninvasive diagnosis. Confirmed vitamin D-binding protein may be one of serum biomarkers of acute rejection. Furthermore, it may provide great insights into understanding the mechanisms and potential treatment strategy of acute rejection.
基金Supported by Health and Family Planning Commission Project of Jilin Province,No.2016Q043Health and Hygiene Committee Project of Jilin Province,No.2021LC082。
文摘BACKGROUND Primary biliary cholangitis(PBC)and autoimmune hepatitis(AIH)are two unexplained immune diseases.The golden standard for diagnosis of these diseases requires a liver biopsy.Liver biopsy is not widely accepted by patients because of its invasive nature,and atypical liver histology can confuse diagnosis.In view of the lack of effective diagnostic markers for PBC and AIH,combined with the increasingly mature metabolomics technologies,including full-contour metabolomics and target.AIM To determine non-invasive,reliable,and sensitive biochemical markers for the differential diagnosis of PBC and AIH.METHODS Serum samples from 54 patients with PBC,26 patients with AIH and 30 healthy controls were analyzed by Ultra-high performance liquid chromatographytandem mass spectrometry serum metabolomics.The metabolites and metabolic pathways were identified,and the metabolic changes,metabolic pathways and inter-group differences between PBC and AIH were analyzed.Fifteen kinds of target metabolites of bile acids(BAs)were quantitatively analyzed by SRM,and the differential metabolites related to the diagnosis of PBC were screened by receiver operating characteristic curve analysis.RESULTS We found the changes in the levels of amino acids,BAs,organic acids,phospholipids,choline,sugar,and sugar alcohols in patients with PBC and AIH.Furthermore,the SRM assay of BAs revealed the increased levels of chenodeoxycholic acid,lithocholic acid(LCA),taurolithocholic acid(TLCA),and LCA+TLCA in the PBC group compared with those in the AIH group.The levels of BAs may be used as biomarkers to differentiate PBC from AIH diseases.The levels of glycochenodeoxycholic acid,glycochenodeoxycholic sulfate,and taurodeoxycholic acid were gradually elevated with the increase of Child-Pugh class,which was correlated with the severity of disease.CONCLUSION The results demonstrated that the levels of BAs could serve as potential biomarkers for the early diagnosis and assessment of the severity of PBC and AIH.
基金国家自然科学基金(21806158)中国计量科学研究院基本科研业务费(AKY1720)+2 种基金博士后基金(2020M670667)Environmental and Lifestyle in Metabolic Health Throughout Life-Course Trajectories(ELEFANT,No.TmuhMEC2016022)中新天津生态城2019年度科技型中小企业升级专项项目资助.
